Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-FXN001 appears to be a code name for a radiopharmaceutical agent labeled with the radioisotope indium-111 (In-111). While there is no direct information in the provided search results about "FXN001" specifically, drugs with similar naming conventions (e.g., 111In-labeled compounds) are typically used as diagnostic radiopharmaceuticals. Indium-111 is commonly used to label molecules such as antibodies or peptides for imaging purposes in nuclear medicine, particularly for detecting sites of infection, inflammation, or tumors. The mechanism of action involves the emission of gamma rays by In-111, which can be detected using gamma cameras to visualize biological processes in vivo. The specific targeting and indication would depend on what FXN001 refers to—likely a proprietary molecule or antibody designed to bind a particular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 111In-FXN001.